Bora Biologics bought Rockville manufacturing site for $122.5 million | The Locally Times
The acquisition of the former MacroGenics facility retains 140 jobs in Montgomery County.
Bora Biologics purchased the former MacroGenics Good Manufacturing Practice facility in Rockville for $122.5 million. The July 13, 2026, Montgomery County government announcement confirms the company retained all 140 employees previously working at the site. The facility holds FDA approval for the production of biologics, which are medical products derived from living organisms. ## Facility Purchase and Employment The $122.5 million transaction covers the purchase of the manufacturing operations. Bora Biologics will continue to produce goods for MacroGenics while adding capacity for other pharmaceutical clients. The county release states the company plans future capital investment at the site, though the document does not provide a timeline for these additions. ## Regional Industry Data Montgomery County records list more than 350 life sciences companies within the county. This cluster is the third-largest in the United States. The Bora Group, based in Taiwan, joins other international firms that operate facilities within the county. County records cite the local workforce and proximity to federal research agencies as factors for the location of these businesses. ## Economic Impact The continued operation of the Rockville site maintains the existing property tax base. While the acquisition does not change school districts or transit routes, the retention of 140 jobs preserves the local labor market. The facility’s capacity for commercial-stage production supports the broader tax revenue used for county services. ## Key Questions **How many jobs were retained at the new facility?** Bora Biologics retained all 140 employees who previously worked at the site. **What is the total cost of the acquisition?** The Bora Group purchased the manufacturing operations for $122.5 million. **What types of products will the facility produce?** The facility is FDA-approved to manufacture clinical and commercial-stage biologics.